Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study

倾向得分匹配 医学 移植 造血干细胞移植 内科学 人口 蕈样真菌病 前瞻性队列研究 外科 淋巴瘤 环境卫生
作者
Adèle de Masson,M. Beylot‐Barry,C. Ram‐Wolff,Jean-Baptiste Mear,Stéphane Dalle,M. D’Incan,S. Oro,Corentin Orvain,Julie Abraham,O. Dereure,Amandine Charbonnier,Jérôme Cornillon,Christine Longvert,Stéphane Barète,S. Boulinguez,E. Wierzbicka-Hainaut,F. Aubin,Marie‐Thérèse Rubio,Marc Bernard,Aline Schmidt-Tanguy,Roch Houot,Anne Pham‐Ledard,David Michonneau,Pauline Brice,Hélène Labussiere‐Wallet,Jean-David Bouaziz,Florent Grange,Hélène Moins-Teisserenc,Katayoun Jondeau,Laurence Michel,Samia Mourah,Maxime Battistella,Etienne Daguindau,Michael Loschi,Alexandra Picard,Nathalie Franck,Natacha Maillard,Anne Huynh,Stéphanie Nguyen,Ambroise Marçais,G. Chaby,Patrice Céballos,Y. Le Corre,Sébastien Maury,Jacques-Olivier Bay,Henri Adamski,Emmanuel Bachy,Edouard Forcade,Gérard Socié,Martine Bagot,Sylvie Chevret,Emmanuel Bachy,Adèle de Masson,M. Beylot‐Barry,Caroline Ram-Wolff,Jean-Baptiste Mear,Stéphane Dalle,M. D’Incan,Olivier Dereure,Corentin Orvain,Julie Abraham,O. Dereure,Amandine Charbonnier,Jérôme Cornillon,Christine Longvert,Stéphane Barète,S. Boulinguez,E. Wierzbicka-Hainaut,François Aubin,Marie-Thérèse Rubio,Marc Bernard,Aline Schmidt-Tanguy,Roch Houot,Anne Pham‐Ledard,David Michonneau,Pauline Brice,Hélène Labussiere‐Wallet,Jean-David Bouaziz,Florent Grange,Hélène Moins-Teisserenc,Katayoun Jondeau,Laurence Michel,Samia Mourah,Maxime Battistella,Etienne Daguindau,Michael Loschi,Alexandra Picard,Nathalie Franck,Natacha Maillard,Anne Huynh,Stéphanie Nguyen,Ambroise Marçais,G. Chaby,Patrice Céballos,Y. Le Corre,Sébastien Maury,Jacques-Olivier Bay,Henri Adamski,Emmanuel Bachy,Edouard Forcade,Gérard Socié,Martine Bagot,Sylvie Chevret,Emmanuel Bachy,Adèle de Masson,M. Beylot‐Barry,Caroline Ram-Wolff,Stéphane Dalle,M. D’Incan,S. Oro,O. Dereure,Christine Longvert,Stéphane Barète,S. Boulinguez,E. Wierzbicka-Hainaut,François Aubin,Anne Pham‐Ledard,Florent Grange,Alexandra Picard,Nathalie Franck,G. Chaby,Y. Le Corre,Henri Adamski,Maxime Battistella,Sylvie Chevret,Jean-Baptiste Mear,Corentin Orvain,Julie Abraham,Amandine Charbonnier,Jérôme Cornillon,Marie-Thérèse Rubio,Marc Bernard,Aline Schmidt-Tanguy,Roch Houot,David Michonneau,Pauline Brice,Hélène Labussiere‐Wallet,Katayoun Jondeau,Etienne Daguindau,Michael Loschi,Natacha Maillard,Anne Huynh,Stéphanie Nguyen,Ambroise Marçais,Patrice Céballos,Régis Peffault de Latour,Emmanuel Bachy,Edouard Forcade,Gérard Socié,Sébastien Maury,Jacques-Olivier Bay
出处
期刊:The Lancet [Elsevier BV]
卷期号:401 (10392): 1941-1950 被引量:24
标识
DOI:10.1016/s0140-6736(23)00329-x
摘要

Advanced-stage cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and fatal diseases. Case series have suggested that allogeneic haematopoietic stem cell transplantation (HSCT) might improve the prognosis of advanced-stage CTCLs. The objective of this study was to investigate the effect of allogeneic HSCT compared with non-HSCT therapy on the outcome of individuals with advanced-stage CTCLs.In this prospective, multicentre, matched controlled trial, conducted at 30 hospitals, participants with advanced CTCLs were allocated treatment: if they had an available compatible related donor they were assigned to allogeneic HSCT, or if not they were allocated to non-allogeneic HSCT therapy. Key inclusion criteria were participants aged 18-70 years, with advanced stage mycosis fungoides or Sézary syndrome, and at least one poor prognostic criteria. Participants were excluded if they were not in complete or partial remission of the disease. Propensity score 1:1 matching with replacement (ie, that each participant treated with HSCT was matched to the participant with the closest propensity score treated with non-HSCT therapy, even if they had already been matched) was used to handle confounding factors, with the balance of covariate distribution between HSCT and non-HSCT groups assessed using standardised mean differences. The primary endpoint was progression-free survival in the matched intention-to-treat population. This trial is registered with ClinicalTrials.gov (NCT02520908), and is currently active but not recruiting.From June 1, 2016, to March 3, 2022, total of 99 participants were enrolled at 17 centres in France. Participants with a sibling or matched unrelated donor were assigned to allogeneic HSCT (HSCT group, n=55 [56%]) and participants without a donor were assigned to non-allogeneic HSCT treatment (non-HSCT group, n=44 [44%]). The median follow-up among survivors was 12·6 months (IQR 11·0-35·2). In the HSCT group, 51 participants (93%) were 1:1 matched to participants from the non-HSCT group. In the intention-to-treat analysis, median progression-free survival was significantly longer in the HSCT group (9·0 months [95% CI 6·6-30·5]) than in the non-HSCT group (3·0 months [2·0-6·3]), with a hazard ratio of 0·38 (95% CI 0·21-0·69; p<0·0001). In the per-protocol population, 40 participants (78%) in the HSCT group had 101 serious events and 29 participants (67%) in the non-HSCT group had 70 serious adverse events. The most common serious adverse event other than graft-versus-host disease in both groups was infections, occurring in 30 participants (59%) in the HSCT group and in 19 participants (44%) in the non-HSCT group.Allogeneic HSCT was associated with significantly longer progression-free survival in participants with advanced-stage CTCLs. These results indicate that allogeneic HSCT treatment should be made available to individuals with high-risk, advanced-stage mycosis fungoides or Sézary syndrome who achieve pre-transplant disease remission.French Ministry of Health, National Cancer Institute, Programme Hospitalier de Recherche Clinique en Cancérologie.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
万能图书馆应助郭小胖14采纳,获得10
刚刚
1秒前
black发布了新的文献求助10
1秒前
梦XING发布了新的文献求助10
1秒前
思睿观通发布了新的文献求助10
1秒前
1秒前
1秒前
2秒前
2秒前
CXQCXQ发布了新的文献求助10
3秒前
大傻春发布了新的文献求助10
4秒前
4秒前
今后应助高lucky采纳,获得10
4秒前
4秒前
啊懂发布了新的文献求助10
4秒前
酷波er应助Rockyhee22采纳,获得10
5秒前
姚姚的赵赵完成签到,获得积分10
5秒前
5秒前
研友_LBKR9n发布了新的文献求助10
6秒前
鱼鱼鱼完成签到,获得积分10
6秒前
ziyu发布了新的文献求助10
6秒前
家伟发布了新的文献求助10
6秒前
JamesPei应助愤怒的含雁采纳,获得10
6秒前
yuiiuy发布了新的文献求助150
6秒前
李健的小迷弟应助77采纳,获得10
6秒前
曹博发布了新的文献求助10
6秒前
ncjdoi发布了新的文献求助10
7秒前
我的文献呢应助Sunwenrui采纳,获得30
7秒前
7秒前
PAD发布了新的文献求助30
7秒前
8秒前
深情安青应助jerkran采纳,获得50
8秒前
风清扬发布了新的文献求助10
8秒前
Akim应助kgrvlm采纳,获得10
8秒前
wjx发布了新的文献求助10
8秒前
9秒前
wangbin743完成签到,获得积分10
9秒前
吭吭唧唧完成签到,获得积分10
9秒前
10秒前
干净的天与完成签到,获得积分10
10秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974844
求助须知:如何正确求助?哪些是违规求助? 3519270
关于积分的说明 11197844
捐赠科研通 3255496
什么是DOI,文献DOI怎么找? 1797791
邀请新用户注册赠送积分活动 877187
科研通“疑难数据库(出版商)”最低求助积分说明 806202